• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

  • in AJO · Audio · Oncology
  • — 7 Nov, 2018
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 
Mohammad Jahanzeb: Real World Use of ALK inhibitors for Lung Cancer
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 
AudioMedica News
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 
00:00 / 9 minutes
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-3710"/>

Subscribe: Apple Podcasts | Spotify | Stitcher

MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry pick” patients to get statistically valid results. This is the conclusion of a retrospective analysis of data reported at the 2018 annual congress of the European Society for Medical Oncology (ESMO). http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=jahanzeb

Progression free survival (PFS) was prolonged to a median of 7.4 months in the overall group of patients treated with ALK-targeted agents. “We were delighted to find out that these patients do as well as patients on clinical trials,” said author Mohammad Jahanzeb MD, Professor of Clinical Medicine, Hematology-Oncology and Medical Director of the University of Miami Sylvester Comprehensive Cancer Center in Deerfield Florida talking to the Audio Journal of Oncology. “Median progression free survival was in the same ball-park as we see in clinical trials.”

Jahanzeb said that prospective clinical trials excluded many real world patients who had comorbid conditions and factors such as brain metastases—which were often encountered among typical real-world patients. “So we thought it was really important to go to a database repository and do a “deep-dive” on the subset of patients positive for ALK,” he said, noting that half of these patients typically had brain metastases.

You may also like...

  • Professor Harry de Koning MD PhD Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent 7 Feb, 2020
  • Rosalind Perrin MD ‘Rescanning’ Optimizes Pencil Beam Proton Delivery to Moving Lung Tumor 12 May, 2015
  • Cora Sternberg Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too 24 Mar, 2013
  • PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer 6 Feb, 2014

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story First Line PARP Inhibition For Ovarian Cancer Assessed
  • Next story Two Drug Combination Doubled Kidney Cancer Progression Free Survival
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Long Overall Survival in Ceritinib-Treated…
    • Ibrutinib: New Frontline Standard for Chronic…
    • Palbociclib Combination Prolongs Life After Breast…
    • BRCA1/2 Ovarian Cancer—Three Years Disease Free with…
    • First Line PARP Inhibition For Ovarian Cancer Assessed
  • Home
  • Oncology
  • AJO
  • ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

© COPYRIGHT 2020 AUDIOMEDICA.COM.